Published mark
Caribou Biosciences, Inc.
NASDAQ: CRBU. Canonical company identity and public leadership record.
US
Record source reportedRecord not claimedNo Eval published
- Alpha ID
- alpha:company:596d3af4-ae1c-47ea-b6a2-8f7228ed6045
- SEC CIK
- 0001619856
- Record version
- vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 16, 2026
- Newest evidence
- Apr 24, 2026
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Rachel Haurwitz, Ph.D.Since Apr 24, 2026
- Chair
- Not published
- Independent
- 7 / 88 directors published
- Published claims
- 302 distinct sources
- Evidence records
- 90 pinned
- Source conflicts
- 0None open
Built from 2 distinct sources and 9 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
CorroboratedSource reportedAlpha inferenceNot disclosed
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
GC CHANGED
Barbara McClung, J.D. executive of Caribou Biosciences, Inc., effective 2026-04-24.
EffectiveEffective Apr 24, 2026E3
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| Chief Legal Officer and Corporate Secretary | Barbara McClung, J.D. | Apr 2026 | current | Source reportedE3 |
| President and Chief Executive Officer | Rachel Haurwitz, Ph.D. | Apr 2026 | current | Source reportedE4 |
| Chief Business Officer | Ruhi Khan, M.B.A. | Apr 2026 | current | Source reportedE5 |
| Chief Financial Officer | Sriram Ryali, M.B.A. | Apr 2026 | current | Source reportedE6 |
| Chief Technology Officer | Timothy C. Barabe, M.B.A. | Apr 2026 | current | Source reportedE7 |
| Chief Medical Officer | Tina Albertson, M.D., Ph.D. | Apr 2026 | current | Source reportedE8 |
Board of directors
Evidence8 directors published. 7 of 8 with a published determination are independent.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Andrew Guggenhime | Independent | 2021 | None published | Source reportedE2 |
| Dara Richardson-Heron | Independent | 2021 | Nominating and Governance | Source reportedE2 |
| David Johnson | Independent | 2022 | Audit | Source reportedE2 |
| Nancy Whiting | Independent | 2021 | Compensation | Source reportedE2 |
| Natalie Sacks | Independent | 2018 | Nominating and Governance, chairNominating and Governance · Chair | Source reportedE2 |
| Rachel Haurwitz | Not independent | 2011 | None published | Source reportedE2 |
| Ran Zheng | Independent | 2021 | Nominating and Governance | Source reportedE2 |
| Scott Braunstein | Independent | 2021 | AuditAudit; Compensation · ChairCompensation, chair | Source reportedE2 |
| Andrew Guggenhime | Independence not published | Not published | Audit, chairCompensation | Source reportedE9 |
Committees and risk ownership
Evidence| Committee | Chair | Members | Risks assigned |
|---|---|---|---|
| Audit | Andrew Guggenhime | Andrew Guggenhime, David Johnson, Scott Braunstein | Not described in the published record |
| Audit; Compensation · Chair | Not published | Scott Braunstein | Not described in the published record |
| Compensation | Scott Braunstein | Scott Braunstein, Andrew Guggenhime, Nancy Whiting | Not described in the published record |
| Nominating and Governance | Natalie Sacks | Natalie Sacks, Dara Richardson-Heron, Ran Zheng | Not described in the published record |
| Nominating and Governance · Chair | Not published | Natalie Sacks | Not described in the published record |
Committee AppointmentAndrew Guggenhime: chair, Audit
Committee AppointmentDavid Johnson: member, Audit
Committee AppointmentScott Braunstein: member, Audit
Committee RecordCompensation: Chair Scott Braunstein; Members Scott Braunstein (Chair); Andrew Guggenhime; Nancy Whiting
Committee AppointmentScott Braunstein: chair, Compensation
Committee AppointmentAndrew Guggenhime: member, Compensation
Committee AppointmentNancy Whiting: member, Compensation
Committee RecordNominating and Governance: Chair Natalie Sacks; Members Natalie Sacks (Chair); Dara Richardson-Heron; Ran Zheng
Committee AppointmentNatalie Sacks: chair, Nominating and Governance
Committee AppointmentDara Richardson-Heron: member, Nominating and Governance
Committee AppointmentRan Zheng: member, Nominating and Governance
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Principal executive officerRachel Haurwitz, Ph.D., President and Chief Executive Officer, from Apr 24, 2026
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
Financials and market context
EvidenceSecurity ListingCRBU (NASDAQ)
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 17, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.
Governance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Legal NameCaribou Biosciences, Inc.
Entity StatusPublic listing published
Published FactUS
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Barbara McClung, J.D.Chief Legal Officer and Corporate Secretarycompany:596d3af4-ae1c-47ea-b6a2-8f7228ed6045:leadership_role:13
- Rachel Haurwitz, Ph.D.President and Chief Executive Officercompany:596d3af4-ae1c-47ea-b6a2-8f7228ed6045:leadership_role:14
- Ruhi Khan, M.B.A.Chief Business Officercompany:596d3af4-ae1c-47ea-b6a2-8f7228ed6045:leadership_role:15
- Sriram Ryali, M.B.A.Chief Financial Officercompany:596d3af4-ae1c-47ea-b6a2-8f7228ed6045:leadership_role:16
- Timothy C. Barabe, M.B.A.Chief Technology Officercompany:596d3af4-ae1c-47ea-b6a2-8f7228ed6045:leadership_role:17
- Tina Albertson, M.D., Ph.D.Chief Medical Officercompany:596d3af4-ae1c-47ea-b6a2-8f7228ed6045:leadership_role:18
- Andrew GuggenhimeDirectorcompany:596d3af4-ae1c-47ea-b6a2-8f7228ed6045:leadership_role:5
- Dara Richardson-HeronDirectorcompany:596d3af4-ae1c-47ea-b6a2-8f7228ed6045:leadership_role:6
- David JohnsonDirectorcompany:596d3af4-ae1c-47ea-b6a2-8f7228ed6045:leadership_role:7
- Nancy WhitingDirectorcompany:596d3af4-ae1c-47ea-b6a2-8f7228ed6045:leadership_role:8
- Natalie SacksDirectorcompany:596d3af4-ae1c-47ea-b6a2-8f7228ed6045:leadership_role:9
- Rachel HaurwitzDirectorcompany:596d3af4-ae1c-47ea-b6a2-8f7228ed6045:leadership_role:10
- Ran ZhengDirectorcompany:596d3af4-ae1c-47ea-b6a2-8f7228ed6045:leadership_role:11
- Scott BraunsteinDirectorcompany:596d3af4-ae1c-47ea-b6a2-8f7228ed6045:leadership_role:12
- Andrew GuggenhimeDirector (committee appointment)company:596d3af4-ae1c-47ea-b6a2-8f7228ed6045:committee_record:19
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 9 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
Claiming not yet available
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 16, 2026. Cited by 4 Claims.
- E2sec proxy. Published Apr 24, 2026. Retrieved Apr 24, 2026. Cited by 8 Claims.
- E3sec filing. Published Apr 24, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
- E4sec filing. Published Apr 24, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
- E5sec filing. Published Apr 24, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
- E6sec filing. Published Apr 24, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
- E7sec filing. Published Apr 24, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
- E8sec filing. Published Apr 24, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
- E9board_seats. board seats. Cited by 12 Claims.
What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 16, 2026- Barbara McClung, J.D. executive of Caribou Biosciences, Inc., effective 2026-04-24.
- Rachel Haurwitz, Ph.D. executive of Caribou Biosciences, Inc., effective 2026-04-24.
- Ruhi Khan, M.B.A. executive of Caribou Biosciences, Inc., effective 2026-04-24.
- Sriram Ryali, M.B.A. executive of Caribou Biosciences, Inc., effective 2026-04-24.
- Timothy C. Barabe, M.B.A. executive of Caribou Biosciences, Inc., effective 2026-04-24.
- Tina Albertson, M.D., Ph.D. executive of Caribou Biosciences, Inc., effective 2026-04-24.
- David Johnson seat on Caribou Biosciences, Inc., effective 2022-01-01.
- David Johnson member of Audit, effective 2022-01-01.
- Andrew Guggenhime seat on Caribou Biosciences, Inc., effective 2021-01-01.
- Dara Richardson-Heron seat on Caribou Biosciences, Inc., effective 2021-01-01.
- Nancy Whiting seat on Caribou Biosciences, Inc., effective 2021-01-01.
- Ran Zheng seat on Caribou Biosciences, Inc., effective 2021-01-01.
- Scott Braunstein seat on Caribou Biosciences, Inc., effective 2021-01-01.
- Audit; Compensation · Chair committee of Caribou Biosciences, Inc., effective 2021-01-01.
- Scott Braunstein member of Audit; Compensation · Chair, effective 2021-01-01.
- Dara Richardson-Heron member of Nominating and Governance, effective 2021-01-01.
- Natalie Sacks seat on Caribou Biosciences, Inc., effective 2018-01-01.
- Nominating and Governance · Chair committee of Caribou Biosciences, Inc., effective 2018-01-01.
- Natalie Sacks member of Nominating and Governance · Chair, effective 2018-01-01.
- Rachel Haurwitz seat on Caribou Biosciences, Inc., effective 2011-01-01.